Myriad Genetics EPS Ratio 2011-2026 | MYGN

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Myriad Genetics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
-3.95	-1.41	-3.18	-1.39	-0.35	-0.71	0.06	1.92	0.25	1.67	1.12	2.33	1.82	1.33	1.12	1.58	0.91	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.33	-3.95	0.184

Quarterly EPS Ratio Myriad Genetics

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-0.36	-0.29	-3.57	-	-	-0.24	-0.41	-0.29	-	-0.75	-1.42	-0.67	-	-0.43	-0.18	-0.26	-	0.31	-0.06	-0.52	-0.5	-0.2	-0.74	-1.55	-0.11	-0.28	-0.11	-0.28	0.04	-0.01	0.04	-0.01	0.45	1.15	0.46	1.18	0.09	-0.01	0.09	-0.02	0.53	0.44	0.43	0.39	0.33	0.22	0.33	0.22	0.67	0.7	0.67	0.7	0.43	0.37	0.43	0.37	0.33	0.29	0.33	0.29

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.18	-3.57	-0.018

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Diagnostics research industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
Enzo Biochem ENZ	-0.51	-	-8.98 %	$ 14.8 K	USA
Centogene N.V. CNTG	-2.06	-	-6.23 %	$ 30.6 M	Germany
Heska Corporation HSKA	-1.92	-	-	$ 1.31 B	USA
Fulgent Genetics FLGT	-1.97	$ 19.5	7.5 %	$ 600 M	USA
Celcuity CELC	-3.79	$ 92.47	3.96 %	$ 4.32 B	USA
Akumin AKU	-1.75	-	-17.87 %	$ 25.9 M	Canada
Co-Diagnostics CODX	-35.2	$ 5.76	11.41 %	$ 7.66 M	USA
Castle Biosciences CSTL	-0.83	$ 21.6	5.93 %	$ 626 M	USA
Aspira Women's Health AWH	-0.37	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	-2.15	-	-61.36 %	$ 2.46 M	USA
Guardant Health GH	-3.32	$ 133.06	4.75 %	$ 16.7 B	USA
Biocept BIOC	-1.89	-	-13.05 %	$ 7.29 M	USA
ICON Public Limited Company ICLR	2.92	$ 152.8	6.18 %	$ 12 B	Irlanda
CareDx, Inc CDNA	-0.4	$ 23.12	3.63 %	$ 1.23 B	USA
Illumina ILMN	5.47	$ 168.06	-1.68 %	$ 26 B	USA
Chembio Diagnostics CEMI	-0.72	-	0.22 %	$ 16.8 M	USA
Check-Cap Ltd. CHEK	0.66	-	-	$ 9.42 M	Israel
Interpace Biosciences IDXG	5.55	$ 1.79	2.29 %	$ 7.92 M	USA
HTG Molecular Diagnostics HTGM	-24.3	-	-20.0 %	$ 1.06 M	USA
Global Cord Blood Corporation CO	4.12	-	-	$ 399 M	China
Genetic Technologies Limited GENE	-0.091	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-1.08	-	0.12 %	$ 80.1 M	China
Mettler-Toledo International MTD	42.2	-	-	$ 24.3 B	Schweiz
DermTech DMTK	-3.09	-	-11.32 %	$ 2.94 M	USA
Lantheus Holdings LNTH	3.46	-	-	$ 6.94 B	USA
NeoGenomics NEO	-0.84	$ 11.31	11.54 %	$ 1.45 B	USA
Charles River Laboratories International CRL	-2.91	$ 185.79	3.29 %	$ 9.21 B	USA
Natera NTRA	-1.52	$ 222.1	4.84 %	$ 30.4 B	USA
Medpace Holdings MEDP	15.6	$ 458.69	1.75 %	$ 13.2 B	USA
Exact Sciences Corporation EXAS	-1.1	-	-	$ 19.8 B	USA
National Research Corporation NRC	50	$ 19.75	3.73 %	$ 442 M	USA
Personalis PSNL	-0.91	$ 12.1	12.24 %	$ 1.08 B	USA
Koninklijke Philips N.V. PHG	0.94	$ 25.99	2.52 %	$ 24.6 B	Niderland
Senseonics Holdings SENS	-1.66	$ 7.01	4.32 %	$ 293 M	USA
QIAGEN N.V. QGEN	1.96	-	-	$ 10.6 B	Niderland
Soleno Therapeutics SLNO	0.4	-	-	$ 2.69 B	USA
Biomerica BMRA	-2.16	-	-	$ 4.94 M	USA
Laboratory Corporation of America Holdings LH	10.5	$ 260.97	0.79 %	$ 21.7 B	USA
Twist Bioscience Corporation TWST	-1.3	-	-	$ 4.42 B	USA
Thermo Fisher Scientific TMO	17.8	$ 482.03	1.7 %	$ 182 B	USA
Motus GI Holdings MOTS	-15.9	-	-34.28 %	$ 263 K	Israel
Neogen Corporation NEOG	-5.03	$ 9.12	3.52 %	$ 1.98 B	USA
Quest Diagnostics Incorporated DGX	8.87	$ 196.12	1.27 %	$ 21.8 B	USA
Invitae Corporation NVTA	-13.2	-	-	$ 21.2 M	USA
Waters Corporation WAT	3.78	$ 376.47	-0.87 %	$ 22.4 B	USA